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Neuronal nicotinic acetylcholine receptors (nAChRs) are a family of ligand-gated ion channels which are widely distributed in the
human brain. Several lines of evidence suggest that two major subtypes (α4β2a n dα7) of nAChRs play an important role in the
pathophysiology of Alzheimer’s disease (AD). Postmortem studies demonstrated alterations in the density of these subtypes of
nAChRs in the brain of patients with AD. Currently, nAChRs are one of the most attractive therapeutic targets for AD. Therefore,
several researchers have made an eﬀort to develop novel radioligands that can be used to study quantitatively the distribution
of these two subtypes in the human brain with positron emission tomography (PET) and single-photon emission computed
tomography (SPECT). In this paper, we discuss the current topics on in vivo imaging of two subtypes of nAChRs in the brain of
patients with AD.
1.Introduction
Alzheimer’s disease (AD) is the most common neurode-
generative disorder in the elderly and has become a major
worldwide health problem. Several reports indicated that it
is aﬀecting almost 1 in 10 individuals over the age of 65 [1],
and as life expectancy increases, over 37 million people suﬀer
with AD, and it is projected to quadruple by 2050 [2]. AD
accounts for over 50% of senile dementia and the majority of
presenile dementia cases and is characterized by progressive
deterioration of higher cognitive functions including the loss
of memory [3, 4].
van Duijn and Hofman [5] reported the inverse relation-
shipbetweensmokinghistoryandearlyonsetAD,suggesting
that smoking may protect against AD [6]. Furthermore,
Rusted and Trawley [7] reported acute improvements
in prospective memory following nicotine administration.
Although Swan and Lessov-Schlaggar [8] discuss the eﬀects
of tobacco smoke and nicotine on cognition in their review,
smoking is associated with increased risk for negative
preclinical and cognitive outcomes in younger people as well
as in older adults. More recently, a meta-analysis including
longitudinal studies published between 1995 and 2007
reportedthatcurrentsmokersrelativetonever-smokerswere
at increased risk of AD, vascular dementia, any dementia,
and cognitive decline, in over the age of 65 [9]. Several lines
of evidence demonstrated that smoking almost doubled the
risk of AD and that smoking cessation might contribute to
a reduction of risk factors for AD and cardiovascular disease
[10, 11]. Noteworthy, the later is also known as a risk factor
forAD.Theseresultssuggestthatsmokingcessationmayplay
an important role in not only primary but also secondary
prevention of AD. In contrast, although the discussion
about neuroprotection by smoking has been continued, it is
possible that nicotinic acetylcholine receptors (nAChRs) in
the brain might play a role in the pathophysiology of AD.
The nAChRs are one of the main classes of AChRs, which
have a pentameric structure composed of ﬁve membrane
spanning subunits, of which nine diﬀerent types have thus
far been identiﬁed and cloned. To date, twelve neuronal
nAChR subunits have been described [12]; nine (α2–α10)
code for subunits [12] based on the presence of adjacent
cysteine residues in the predicted protein sequences, in a
regionhomologoustotheputativeagonist-bindingsiteofthe
muscle, a subunit (α1) and three referred to as non-α or β-
subunits (β2–β4). Among the several nAChR subtypes in the
human central nervous system (CNS), the heteromeric α4β2
and homomeric α7s u b t y p e s( Figure 1) are predominant in
the brain [13, 14]. It has been reported that other subtypes
(e.g., α3, α6) exist in the brain [15, 16] and that α6s u b t y p e2 International Journal of Alzheimer’s Disease
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Figure 1: Structures of α4β2 nAChR (a) and α7 nAChR (b).
might be mainly involved in the pathophysiology of Parkin-
son’s disease [16]. Furthermore, studies using postmortem
human brain samples have demonstrated alterations in the
levels of α4a n dα7 nAChR in the brains of patients with
AD [15, 17–19]. Despite its lower number, loss of α3s u b t yp e
consistentwithα4andα7nAChRsubtypeswasalsoobserved
in the brains of patients with AD [15]. Taken together, it is
likelythatthesetwosubtypes(α4β2andα7)ofnAChRmight
play a role in the pathogenesis of AD. Therefore, it is of great
interest to examine whether these two subtypes of nAChR
are altered in the living brain of patients with AD using brain
imaging techniques.
In this paper, we discuss the recent ﬁndings on imaging
of these two nAChRs (α4β2a n dα7) in the brain with
AD using positron emission tomography (PET) and single-
photon emission computed tomography (SPECT).
2. α4β2nA Ch RsS ubtype
2.1.RelationshipbetweenAmyloid-β andα4β2nAChR. Amy-
loid β protein (Aβ) is a major constituent of senile
plaques and one of the candidates for the cause of the
neurodegeneration found in AD. It has been shown that
the accumulation of Aβ precedes other pathological changes
and causes neurodegeneration or neuronal death in vitro
and in vivo [20, 21] .T h el o s so fm e m o r ys e e ni nA Di s
thought to be associated with Aβ-induced impairment of
synaptic plasticity such as long-term potentiation (LTP) in
the hippocampus. There are lines of evidence suggesting that
nAChR activation provides protection against Aβ-induced
neurotoxicity in cultured cortical neurons [22, 23]. These
results indicated that nicotine protects against Aβ-induced
neuronal death, and similar eﬀect has been also observed
in those selective α4β2 nAChR agonists such as cytosine
and epibatidine, but this neuroprotection is blocked by
theselectiveα4β2nAChRantagonistdihydro-β-erythroidine
(DHβE). Moreover, recently, Wu et al. [24]i n v e s t i g a t e da
p o s s i b l er o l eo fα4β2 nAChR in mediating the impairment
of long-term potentiation (LTP) by various forms of Aβ in
in vivo. They reported that intracerebroventricular injection
of Aβ40,A β25−−35,o rA β31−−35 signiﬁcantly suppressed high-
frequency stimulation-induced LTP. Similarly, epibatidine
dose dependently suppressed the induction of LTP. Whereas
DHβE showed no eﬀect on the induction of LTP, it
signiﬁcantly reversed Aβ31−−35-induced LTP impairment.
These ﬁndings suggest that α4β2 nAChR, which can be
directly activated by Aβ,i sr e q u i r e df o rA β suppression of
LTP in vivo. The mechanisms by which nicotine enhanced
the inhibition of LTP by Aβ were not clear. A possible
explanation is that nicotine could activate nAChRs present
in inhibitory interneurons, thereby potentiating inhibitory
inputs to hippocampal neurons.
2.2. Cognition and α4β2 nAChR Agonists. It is likely that
reduced density of nAChR is related to dementia severity,
assessed using a global rating. Nicotine has been postulated
to be a possible treatment for AD, improving cognition
in humans [25]. Recently, Loughead et al. [26]r e p o r t e d
novel evidence that the α4β2 partial agonist varenicline
increased working memory-related brain activity after 3
days of nicotine abstinence, particularly at high levels of
task diﬃculty, with associated improvements in cognitive
performance among highly dependent smokers.
2.3. Postmortem Studies of α4β2 nAChR in the Brain of
Patients with AD. Not only transmitter release but also
receptor-binding sites may be altered in the brain of AD
patients [27–29]. Postmortem studies showed the reduction
(up to 50%) of α4β2 subtype of nAChRs in brain of patients
withAD[30],anditmayoccurveryearlyinthecourseofAD
[31]. Both α4a n dα7 subunits are known to be important
constituents in α4β2a n dα7 receptor subtypes, respectively.
Investigation using the autopsy samples of human cerebral
cortex has clearly shown that these two subtypes (α4a n dα7
isoforms) are signiﬁcantly decreased in their protein amount
in the cortices of AD patients [15, 19, 32].
2.4. Imaging of α4β2n A C h RS u b t y p e .Considering the role
of α4β2 nAChR in the pathophysiology of AD, it is of
great interest to study α4β2 nAChR in the living human
brain using PET/SPECT. Much eﬀort has been devoted
to visualize α4β2 nAChR in the brain by PET/SPECT.
Currently, two PET ligands, including [11C]nicotine and
2-[18F]ﬂuoro-3-(2(S)azetidinylmethoxy)pyridine(2-[18F]F-
A-85380), and a SPECT ligand, 5-[123I]iodo-3-(2 (S)-2-
azetidinylmethoxy)pyridine (5-[123I]I-A-85380), (Figure 2)
for in vivo imaging of α4β2 nAChR in the human brain have
been used in clinical studies [33–35].
2.5. [11C]Nicotine. The development of radiolabelled nico-
tine [36, 37] has allowed for evaluating the uptake and
distribution of nAChR in the living human brain [38–40].
The data obtained by [11C]nicotine is generally consistent
with the known pattern of nAChR measured by in vitro
binding in autopsy brain tissue [39]. [11C]nicotine-PET has
beenusedtostudyα4β2nAChRinhumanbrain,andasevere
loss of the nAChR has been detected in the brain of patients
with AD [13]. Cortical nAChRs in mild AD patients are
robustly associated with the cognitive function of attention
[35] and have revealed a signiﬁcant negative correlation
between severity of cognitive impairment and density of
brain nAChR [40]. It will be, therefore, of interest to study
an alteration in α4β2 nAChR at a presymptomatic stage of
AD. Furthermore, the in vivo cortical AChE inhibition andInternational Journal of Alzheimer’s Disease 3
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Figure 2: Chemical structures of radioligands for nAChRs.
[11C]nicotine binding were associated with changes in the
attention domain of cognition rather than episodic memory
when administering galantamine [41]. Thus, [11C]nicotine-
PET may be also used for monitoring treatment eﬃcacy in
AD patients [41, 42].
Unfortunately, [11C]nicotine displays high levels of non-
speciﬁc binding, rapid metabolism, and rapid washoutof the
brain [43]. The heterogeneity of [11C]nicotine binding in the
brain also precludes the identiﬁcation of a reference region
which may be used to accurately determine nonspeciﬁc
binding. Taken together, it is unlikely that [11C]nicotine
might be a suitable PET ligand for in vivo imaging of α4β2
nAChR in human brain.
2.6. 2-[18F]F-A-85380 and 5-[123I]I-A-85380. A-85380 [3-
(2(S)-azetidinylmethoxy) pyridine] is a potent and selective
agonist with high aﬃnity for α4β2 nAChR subtype and low
aﬃnity for other nAChR subtypes [44]. A-85380 is eﬀective
in a wide range of preclinical models of CNS disorders
[45, 46]. Recently, A-85380 was successfully labeled using
18Fo r125/123Iw i t hah i g ha ﬃnity (Ki = 50pM for F and
Ki = 15pM for I) for α4β2 nAChR [44, 47, 48]. These
radioligands have been evaluated in vitro and in vivo as
PET/SPECT radioligands to visualize α4β2 nAChR subtype
in the brain [49, 50]. In healthy nonsmoking human brain,
both 2-[18F]F-A85380 and 5-[123I]I-A85380 have revealed a
pattern of highest uptake in the thalamus, intermediate in
the midbrain, pons, cerebellum, and cortex, and lowest in
white matter [50–52], which is consistent with the regional
distribution of α4β2 nAChR.
Furthermore, a study of age-related decline in nicotinic
receptor availability showed that regional β2 nAChR avail-
ability were inversely correlated with decline ranging from
32% (thalamus) to 18% (occipital cortex) over the adult
lifespan, or up to 5% per decade [53]. These results may
corroborate postmortem reports of decline in high-aﬃnity
nicotine binding with age and may aid in elucidating the
role of β2-nAChR in cognitive aging. In addition, 2-[18F]F-
A-85380 or 5-[123I]I-A-85380 have been used to evaluate
the eﬀect of smoking on occupancy of α4β2 nAChR [54,
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Figure 3: Comparison with regional uptake values of 5-
[123I]I-A85380 in age-matched healthy control and patients with
Alzheimer’s disease. Signiﬁcant bilateral reductions in nicotinic
receptor binding were identiﬁed in frontal, striatal, right medial
temporal, and pons in patients with AD compared to controls.
(DataisfromthepaperofO’Brienetal.[59].) ∗P<. 05, ∗∗P<. 005,
∗∗∗P<. 001.
55]. Smoking 0.13 (1 to 2 puﬀs) of a cigarette resulted
in 50% occupancy of α4β2 nAChR for 3.1 hours after
smoking. Smoking a full cigarette (or more) resulted in
more than 88% receptor occupancy and was accompanied
by a reduction in cigarette craving. The extent of receptor
occupancy found herein suggests that smoking may lead
to withdrawal alleviation by maintaining nAChR in the
desensitized state.
Both 2-[18F]F-A-85380 and 5-[123I]I-A-85380 have been
used in AD patients [51, 56–60]. In 17 patients with
moderate to severe AD and 6 subjects with amnestic mild
cognitive impairment (MCI) compared with 10 healthy
controlsubjects,Sabrietal.[56]foundsigniﬁcantreductions
of α4β2 nAChR in brain regions (hippocampus, caudate,
frontal cortex, temporal cortex, posterior cingulate, anterior
cingulate, and parietal cortex) in the brain of AD by using
2-[18F]F-A-85380. Most recently, Kendziorra et al. [57]
reported that both patients with AD and those with MCI
showed a signiﬁcant reduction in 2-[18F]F-A-85380 binding
potential in typical AD-aﬀected brain regions and that the 2-
[18F]F-A-85380bindingpotentialcorrelatedwiththeseverity
of cognitive impairment. In addition, only MCI patients
who converted to AD in the later course (n = 5) had a
r e d u c t i o ni n2 - [ 18F]F-A-85380 binding potential. Thus, it
is likely that 2-[18F]F-A-85380 PET might give prognostic
information about a conversion from MCI to AD. Similar
ﬁndings were also reported by 5-[123I]I-A-85380, showing
signiﬁcant reductions in the activity ratios of the region of
interest to cerebellum in the frontal, striatal, right medial
temporal, and pontine regions in 16 patients with AD
compared with 16 healthy control subjects [59]( Figure 3).
These ﬁndings suggest that a reduction in α4β2n A C h R4 International Journal of Alzheimer’s Disease
occurs during symptomatic stages of AD and that the α4β2
nAChR availability in these regions correlated with the
severity of cognitive impairment. In contrast, there were no
diﬀerences in distribution volume (DV) of nAChR between
the healthy controls and early AD patients (Figure 4)[ 51,
58].
2-[18F]F-A-85380PEThasbeenusedtoobserveoutcome
of drug treatment for the improvements of cognition
in patients with mild AD [61]. However, no signiﬁcant
correlations were found between cognitive measures and
nAChR simpliﬁed DV (Figure 5). These results are similar
to the results reported by Kadir et al. [41] in their studies
using [11C]nicotine. The relationship between cognition
in AD and cholinergic dysfunction may be related to a
numberoffactors,includingthedegreeofcholinergicsystem
(or receptor) loss, the other nAChR subtypes, or other
neurochemical systems.
3. α7nA ChRS ubtype
3.1. Relationship between Aβ and α7 nAChR. Of the two
major subtypes of nAChRs in the CNS, α7 subtype has
lower aﬃnity for ACh compared to α4β2s u b t y p e[ 62].
Accumulating evidence suggests that α7 nAChR plays a role
in the pathophysiology of AD. Aβ has picomolar aﬃnity
for α7 nAChR [63, 64], which results in the formation of
Aβ-α7 nAChR complex. This complex is known to move
intracellularlyandcauseneurotoxicity[63–65].Interestingly,
this neurotoxicity is not present in transgenic mouse model
of AD overexpressing a mutated form of the human amy-
loid precursor protein (APP) and lacking the α7n A C h R
[66]. Recently, Bencherif and Lippiello [67] pointed out
that the α7-JAK2-(NF-κB; STAT3)-Bcl2 prosurvival pathway
is important for the neuroprotective role of α7n A C h R
(Figure 6). By blocking cytosolic cytochrome C, which is
released from the mitochondria via Aβ1−−42,B c l 2f u l l y
counteracts the Aβ1−−42-induced apoptosis of cells [68]. The
fact that this antiapoptotic pathway is further related with
ApoE4 [69], GSK-3β-activated tau phosphorylation [70],
and Wnt signaling pathways [71] denotes the critical role of
α7 nAChR in pathophysiology of AD.
The 3xTg-ADmice [72], whicharetriple transgenic mice
expressing APP, presinilin-1, and Tau, were shown to have an
age-dependent reduction of α7 nAChR. This reduction was
limited to brain regions where intraneuronal Aβ42 accumu-
lation occurred [73]. The early cognitive deﬁcits of 3xTG-
AD mice also correlate with intracellular Aβ accumulation,
and the clearing of this Aβ accumulation by immunotherapy
reverses the early cognitive impairment [74].
Tg2576 transgenic mice (APPswe) dramatically reduced
Aβ plaque expression with chronic administration of nico-
tine for 5.5 months [75]. It is further reported that a 10-day
administration of nicotine reduced the guanidinium-soluble
Aβ levels by 46 to 66%, whereas the intracellular Aβ levels
remained unchanged [76]. This treatment with nicotine
also resulted in less glial ﬁbrillary acidic protein- (GFAP-)
immunoreactive astrocytes around the amyloid plaques and
increased numbers of α7 nAChR in the cortex of APPswe
mice [76]. Bencherif [68] points out the importance of these
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Figure 4: Regional α4β2-nAChR availability (VT)o f5 - [ 123I]I-
A85380 in age-matched healthy control (HC), mild cognitive
impairment (MCI), and Alzheimer’s disease (AD) groups. No
signiﬁcant regional diﬀerences among the subject groups for any of
the 8 regions, including the 4 neocortical regions, were identiﬁed.
(Data is from the paper of Mitsis et al. [58].)
data, as reduction of Aβ with anti-Aβ antibody treatment is
reported to rapidly recover the associated neuritic dystrophy
in living animals [77].
Orr-Urtregeretal.[78]generatedα7nAChRgeneknock-
out (KO) mice, and the resulting α7 nAChR KO mice did not
show any morphological central nervous system abnormal-
ities [78, 79], but behavioral tests point out some cognitive
deﬁcitsinKOmice,suchasimpairedsustainedattention[80,
81], impairment in working memory [82], and impairment
in performance under high attentional demand [83]. The
cognitive deﬁcits seen in APP transgenic mice worsen when
α7 nAChR is absent at the same time [84]. These α7n A C h R
KO APP mice showed signiﬁcant reduction in hippocampal
and basalforebrain choline acetyltransferaseactivity and loss
of hippocampal neurons and markers; stereological analyses
indicated more pronounced loss of hippocampal pyramidal
neurons and volume loss compared with APP mice [84].
Taken all together, it is likely that α7 nAChR might play an
important role in the process of Aβ disposition which was
detected in the brain of patients with AD.
3.2. Cognition and α7 nAChR Agonists. An u m b e ro fα7
nAChR agonists are reported to improve recognition mem-
oryinrodents.Theseagonistsincludetropisetron[85],ABBF
[86], AR-R 17779 [87], SSR180711 [88, 89], A-582941 [90],
andSEN123333[91].Innonhumanprimates,improvements
in long-delay performance of delayed matching tasks are
reported by α7 nAChR agonists GTS-21 [92] and A-582941
[93].
It is reported that nicotine inhibits Aβ deposition and
aggregation in the cortex and hippocampus of APP trans-
genic mice [94]. RNA interference experiments indicatedInternational Journal of Alzheimer’s Disease 5
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Figure 5: Regional nAChR simpliﬁed distribution volume (DV(s))
of2-[18F]F-A85380inhealthycontrol(HC)andAlzheimer’sdisease
(AD) groups. No signiﬁcant diﬀerence in nAChR DV(s) was found
between both groups. (Data is from the paper of Ellis et al.
[51].)
that these nicotine-mediated eﬀects require α7 nAChR. In
anotherstudy[70],theselectiveα7nAChR agonistA-582941
led to increased phosphorylation of the inhibitory regulating
amino acid residue Ser-9 on glycogen synthase kinase 3β
(GSK3β), a major kinase responsible for tau hyperphospho-
rylation in AD neuropathology. This was observed in mouse
cingulate cortex and hippocampus and was not observed
in α7 nAChR KO mice. S9-GSK3β phosphorylation was
also seen in the hippocampus of Tg2576 (APP), as well
as wild-type mice by steady-state exposure of A-582941.
Moreover, continuous infusions of A-582941 decreased
phosphorylation of tau in hippocampal CA3 Mossy ﬁbers
in a hypothermia-induced tau hyperphosphorylation mouse
model and also decreased spinal motoneurons in AD double
transgenic APP/tau mouse line. This group points out that
α7 nAChR agonists may have therapeutic potential through
GSK3β inhibition followed by reduction of tau hyperphos-
phorylation and further suggest that this pharmacology may
havethe potential to provide disease modifying beneﬁt in the
treatment of AD.
It is reported that the α7 nAChR agonist GTS-21
prevented Aβ25−−35-induced impairment of acquisition per-
formance and probe trail test in Morris water maze [95].
Their study showed ﬁrst in vivo evidence that treatment
with GTS-21 ameliorates the Aβ-induced deﬁcit in spatial
cognition through not only activating α7 nAChR but also
preventing the Aβ-impaired α7 nAChR.
Using anovel selectiveα7 nAChR partial agonist S 24795,
Wang et al. [96] showed that, in contrast to anti-AD drugs,
galantamine (a cholinesterase inhibitor) and memantine
(an N-methyl-D-aspartate (NMDA) receptor antagonist),
S 24795 reduced or limited Aβ42-α7 nAChR association,
Aβ42-induced tau phosphorylation, Aβ42 accumulations,
and Aβ42-mediated inhibition of α7n A C h RC a 2+ inﬂux
in rodent brain [96]. S 24795 more importantly restored
α7 nAChR functional deﬁcits which had resulted from
continued exposure to exogenous Aβ42.
Taken all together, α7 nAChR is one of the therapeutic
targets for AD [97, 98].
3.3. Postmortem Studies of α7 nAChR in the Brain of Patients
with AD. In the postmortem brain of patients with AD,
decline of α7 nAChR appears early in the disease and was
associated with the progression of cognitive deﬁcits [99–
101]. Although the protein levels are reduced in the cortex
and hippocampus of AD patients [15, 19, 32, 100, 102],
contradictions arise at the level of gene transcription. For
example, levels of α7 nAChR protein were reduced by 36%
in the hippocampus of AD patients [15], but α7n A C h R
mRNA expression is increased by 65% [18]. Furthermore,
no diﬀerences in [125I]α-bungarotoxin binding were found
in the frontal cortex of AD patients [103] and negative
reduction of the α7n A C h Rp r o t e i nl e v e l s[ 104].
3.4. Imaging of α7 nAChR in the Brain. Given the role
of α7 nAChR in the pathogenesis of AD, it is of great
interest to study α7 nAChR in the living human brain using
PET/SPECT. Much eﬀort has been devoted to visualize α7
nAChR in the brain by PET/SPECT, but the development
of a radioligand that depicts α7 nAChR speciﬁcally has
been problematic due to its relatively low amount in the
brain [105–108]. Generally, α-bungarotoxin and MLA are
well known as speciﬁc α7 nAChR antagonists. However,
due to their large molecular weights, they have diﬃculty
passing through the blood-brain barrier which makes them
unfavorable for radioligands [109–111]. Consequently, a
number of radioligands for α7 nAChR are being developed
and evaluated as PET/SPECT radioligand. However, all
radioligands except [11C]CHIBA-1001 were unsuccessful
[112].
3.5. [11C]CHIBA-1001 as a Novel PET Ligand for α7 nAChR.
We developed a novel PET ligand, 4-[11C]methylphenyl 1,4-
diazabicyclo[3.2.2.]nonane-4-carboxylate ([11C]CHIBA-
1001) (Figure 7). A PET study using conscious monkeys
demonstrated that the distribution of radioactivity in
the brain regions after intravenous administration of
[11C]CHIBA-1001 was blocked by pretreatment with the
selective α7 nAChR agonist SSR180711 (5.0 mg/kg), but
not the selective α4β2 nAChR agonist A85380 (1.0mg/kg)
[89]. In addition, we reported that the order of drugs for
the inhibition of [3H]CHIBA-1001 binding to rat brain
membranes was similar to α7 nAChR pharmacological
proﬁles [113]. We also reported a preliminary PET study
of [11C]CHIBA-1001 in a healthy human [114, 115]. Very
recently, we reported that [125I]CHIBA-1006, an iodine
derivative of SSR180711, has a high aﬃnity for α7n A C h R
as compared with CHIBA-1001 [116]. Considering the
good brain permeability of derivatives (e.g., SSR180711 and
CHIBA-1001) of CHIBA-1006, it would be of great interest6 International Journal of Alzheimer’s Disease
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to examine whether [123I]CHIBA-1006 and [124I]CHIBA-
1006 are suitable radioligands for in vivo labeling of α7
nAChRs in the brain using SPECT and PET, respectively
[116].
At present, [11C]CHIBA-1001 is the only PET lig-
and which can be available for in vivo study of α7
nAChRs in intact human brain [114]. PET studies of
[11C]CHIBA-1001 in patients with AD are currently under-
way with [11C]Pittsburgh compound D ([11C]PiB)-PET
and [18F]ﬂuorodeoxyglucose ([18F]FDG)-PET. This study
aims to evaluate the relationship between the distribution
of α7 nAChR (assessed by [11C]CHIBA-1001) and Aβ
disposition (assessed by [11C]PiB), while estimating the
stage and cognitive levels (assessed by [18F]FDG-PET and
neuropsychological examinations) for each AD patient.
4. Conclusions
Considering the importance of early prevention of onset of
AD, it is very important to detect alternations in nAChRs
at the presymptomatic stage of AD. In patients with MCI,
the early detection and early therapeutic intervention would
be beneﬁcial. Therefore, brain imaging of nAChRs using
PET and SPECT will be a powerful tool to study the
mechanisms underlying pathological brain processes of
cognitivedisturbancesinthesepatients.Currently,somePET
and SPECT ligands for both subtypes (α4β2 nAChR and α7
nAChR)havebeenusedtoinvestigatethechangesinreceptor
densities and functions of patients with AD. Gaining a better
understanding of the role of nAChRs in the pathophysiology
of AD is expected to provide new perspectives for treating
this disorder.
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